A Two Stage Phase Ib Study to Investigate the Pharmocokinetics and Tolerability of Rituximab Subcutaneous Formulation in Pats With Follicular Lymphoma as Part of Maintenance Treatement.
Interventional
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
C trough
At intervals up to day 84
No
Clinical Trials
Study Director
Hoffmann-La Roche
Ecuador: Public Health Ministry
BP22333
NCT00930514
September 2009
June 2013
Name | Location |
---|